Abbott Laboratories (ABT) — closed signal from July 11, 2025
Partial Published before the outcome was known, scored automatically when the window closed on October 9, 2025.
Predicted vs. what happened
What happened
Reached 24% of the predicted growth at its peak, without hitting the target.
The thesis — published July 11, 2025
After a small 7% slide caused by talk about new weight-loss drugs, Abbott shares sit near $132, a level that often holds. The Libre 3 Plus glucose monitor launches in Canada on 10 July and could reignite its diabetes business. Investor mood is unusually high, and similar setups have led to roughly 13% rebounds. Because the stock is about 10% cheaper than peers, a move toward $150 within three months seems realistic.
Primary drivers
- New Libre 3 Plus launch grows potential customer base, easing weight-loss drug worries.
- Oversold signal and very bullish mood have repeatedly led to quick double-digit gains.
- Shares are about 10% cheaper than similar medical-tech firms, giving price cushion.
- July-Aug earnings update could spark fresh attention and lift the share price.
How it played out
ABT: the 14% target was not reached
Lyra published ABT at $132.41 on 2025-07-11 with a short-term thesis for 14% growth toward $149.61. The thesis pointed to the Libre 3 Plus launch in Canada, worries around weight-loss drugs easing, very bullish mood, an oversold setup, a valuation about 10% cheaper than similar medical-tech firms, and a July-Aug earnings update as possible support.
Inside the window, ABT peaked at $136.88 on 2025-09-22, a 3.4% gain. It stayed below the target and never reached $149.61. The window ended at $132.72. The thesis only partially played out.
What happened during the window
On 2025-07-17, Abbott reported second-quarter sales of $11.14 billion and adjusted earnings of $1.26 per share, while narrowing its full-year adjusted earnings outlook to $5.10 to $5.20. On the same date, Investopedia reported that Abbott shares fell after the narrowed outlook, even though second-quarter revenue and adjusted earnings exceeded analyst forecasts.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.